Determinants of Mortality in Epithelial Ovarian Cancer: Systematic Review and Meta-analysis (Last 5 Years)
Abstract
ABSTRACT
Background: Ovarian cancer, ranking third among gynecologic cancers, poses a significant global health challenge. Despite affecting over 239,000 annually and causing 150,000 deaths, the overall survival rate is 45.6%. Variability in survival rates across different stages necessitates a detailed understanding of contributing factors. This systematic review and meta-analysis explores recent research to illuminate crucial aspects influencing epithelial ovarian cancer (EOC) patient outcomes.
Methods: A protocol registered in PROSPERO (ID: CRD42024502616) guided this systematic review, focusing on cohort studies examining prognostic factors for EOC mortality. Eligibility criteria included relevance to mortality risk, clear extraction methods, and English language. A PRISMA-guided search with the keywords “((Ovarian Cancer) AND (Mortality) AND (Risk)” across Scopus, PubMed, and Cochrane. Evaluation of 66,191 samples from 16 cohort studies identified several key prognostic factors for mortality in epithelial ovarian cancer (EOC).
Results: Advanced FIGO stage (III-IV) and high-grade serous histology were significant predictors of higher mortality, with stage III-IV showing a risk ratio of 3.62 (95% CI 3.35–3.91). Older age, greater inflammation (higher BMI, smoking), and bilateral tumors also increased mortality risk. Additionally, lifestyle factors like reduced physical activity and rural living, as well as treatment-related factors such as perioperative red blood cell transfusion, were associated with poorer survival outcomes. This systematic review provides comprehensive insights into the complex landscape of EOC survival. Key prognostic factors for mortality in EOC patients include advanced cancer stage, high-grade serous histology, older age, inflammation, and bilateral tumors. Treatment factors such as perioperative transfusion and neoadjuvant chemotherapy intensity also play a critical role.
Conclusion: These findings highlight the need for personalized treatment strategies based on these factors to improve survival outcomes for EOC patients.
Downloads
References
Andreou,M.,Kyprianidou,M.,Cortas,C.,Polycarpou,I.,Papamichael,D.,Kountourakis,P.,et al.(2023).Prognostic factors and survival in ovarian cancer.Cancers,15(24),5710.https://doi.org/10.3390/cancers15245710
Sait,K.H.,Alam,M.Z.,Haque,A.,Sait,H.K.,Sait,M.K.,&Anfinan,N.M.(2022).Survival and prognostic factors in epithelial ovarian cancer. Saudi Medical Journal,43(2),146–155. https://doi.org/10.15537/smj.2022.43.2.20210747
Momenimovahed,Z.,Tiznobaik,A.,Taheri,S.,&Salehiniya,H.(2019).Epidemiology and risk factors of ovarian cancer.International Journal of Women’s Health,11,287–299.https://doi.org/10.2147/IJWH.S197604
Ali,A.T.,Al-Ani,O.,&Al-Ani,F.(2023).Epidemiology and risk factors for ovarian cancer.Przeglad Menopauzalny,22(2),93–104.https://doi.org/10.5114/pm.2023.127071
Kim,S.J.,Rosen,B.,Fan,I.,Ivanova,A.,McLaughlin,J.R.,Risch,H.,et al.(2017).Epidemiologic predictors of survival in epithelial ovarian cancer.British Journal of Cancer,116(7),964–971.https://doi.org/10.1038/bjc.2017.36
Gaitskell,K.,Hermon,C.,Barnes,I.,Pirie,K.,Floud,S.,Green,J.,et al.(2022).Ovarian cancer survival by stage and histotype.Cancer Epidemiology,76,102074.https://doi.org/10.1016/j.canep.2021.102074
Huang,W.,Bao,Y.,Luo,X.,Yao,L.,&Yuan,L.(2023).Prognosis of ethnic Chinese older adults with epithelial ovarian cancer.Journal of Ovarian Research,16(1),110.https://doi.org/10.1186/s13048-023-01163-4
Zhu,C.,Zhu,J.,Qian,L.,Liu,H.,Shen,Z.,Wu,D.,et al.(2021).Prognosis of ovarian clear cell carcinoma.BMC Cancer,21(1),322.https://doi.org/10.1186/s12885-021-08057-7
Brieger,K.K.,Phung,M.T.,Mukherjee,B.,Bakulski,K.M.,Anton-Culver,H.,Bandera,E.V.,et al.(2022).Inflammation-related risk score and ovarian cancer survival.Cancer Epidemiology, Biomarkers & Prevention,31(2),443–452.https://doi.org/10.1158/1055-9965.EPI-21-0893
Ekmann-Gade,A.W.,Høgdall,C.K.,Seibæk,L.,Noer,M.C.,Fagö-Olsen,C.L.,&Schnack,T.H.(2022).Survival trends in epithelial ovarian cancer by age group.Gynecologic Oncology,164(1),120–128.https://doi.org/10.1016/j.ygyno.2021.10.028
Lutgendorf,S.K.,Ramirez,E.,Schrepf,A.,Valentine,M.C.,Charlton,M.,Zimmerman,M.B.,et al.(2021).Rural residence and survival in epithelial ovarian cancer.Gynecologic Oncology,163(1),22–28.
Wang,T.,Townsend,M.K.,Eliassen,A.H.,Terry,K.L.,Song,M.,Irwin,M.L.,et al.(2021).Physical activity and survival after ovarian cancer diagnosis.International Journal of Cancer,149(5),1067–1075
Zheng,Y.,Zhang,W.,Chen,Y.,Yang,X.,&Dong,R.(2023).Perioperative blood transfusion and prognosis in epithelial ovarian cancer.Heliyon,9(12),e23081.
Melamed,A.,Rauh-Hain,J.A.,Gockley,A.A.,Nitecki,R.,Ramirez,P.T.,Hershman,D.L.,et al.(2021).Neoadjuvant chemotherapy use and overall survival in advanced ovarian cancer.JAMA Oncology,7(12),1782–1790.
Birge,Ö.,Bakır,M.S.,Doğan,S.,Tuncer,H.A.,&Simsek,T.(2022).Fertility-sparing surgery outcomes in early-stage ovarian cancer.Journal of Ovarian Research,15(1),135.
Kajiyama,H.,Suzuki,S.,Yoshikawa,N.,Kawai,M.,Mizuno,K.,Yamamuro,O.,et al.(2019).Fertility-sparing surgery outcomes in early-stage ovarian cancer.BMC Cancer,19(1),1235.
Okunade,K.S.,John-Olabode,S.,Ohazurike,E.O.,Soibi-Harry,A.,Osunwusi,B.,&Anorlu,R.I.(2022).Predictors of early mortality in epithelial ovarian cancer.Health Science Reports,5(4),e717.
Dilley,J.,Burnell,M.,Gentry-Maharaj,A.,Ryan,A.,Neophytou,C.,Apostolidou,S.,et al.(2020).Symptoms, diagnostic routes, and survival in ovarian cancer.Gynecologic Oncology,158(2),316–322.
Elias,K.M.,Guo,J.,&Bast,R.C.(2018).Early detection of ovarian cancer.Hematology/Oncology Clinics of North America,32(6),903–914.
Præstegaard,C.,Jensen,A.,Jensen,S.M.,Nielsen,T.S.S.,Webb,P.M.,Nagle,C.M.,et al.(2017).Cigarette smoking and survival in ovarian cancer.International Journal of Cancer,140(11),2422–2435.
Dou,S.,Chen,J.,Wang,Y.,Zhu,C.,Cui,H.,&Li,Y.(2022).Intraoperative blood loss risk factors in ovarian cancer surgery.Gynecology and Obstetrics Clinical Medicine,2(1),9–13.
Crafton,S.,Cohn,D.E.,Llamocca,E.N.,Louden,E.,Rhoades,J.,&Felix,A.S.(2020).Fertility-sparing surgery and survival in epithelial ovarian cancer.Cancer,126(6),1217–1224
Copyright (c) 2026 Fitriyadi Kusuma, Kemal Akbar Suryoadji, Nadia Ayu Mulansari, Garry Soloan, Kieran Pasha Ivan Sini, Anisa Saphira Wulandari, Vira Nur Arifa, Marshaly Safira Masrie, Fahrayhansyah Muhammad Faqih, Bintang Wirawan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright and License Statement
By submitting a manuscript to the Journal of Applied Holistic Nursing Science, the author agrees to this policy. No specific document approval is required.
Copyright:
Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional
The copyright for any article in the Journal of Applied Holistic Nursing Science is fully held by the author under the Creative Commons CC BY-NC-SA 4.0 license.
1. The copyright of each article belongs to the author.
2. Authors retain all rights to their published work, including but not limited to the rights outlined on this page.
3. The author acknowledges that Journal of Applied Holistic Nursing Science is the first publisher under the Creative Commons Attribution 4.0 International License (CC BY-NC-SA-4.0).
4. Authors may separately submit their work, arrange for non-exclusive distribution of the manuscript previously published in this journal into other versions (e.g., submission to the author's institutional repository, publication in books, etc.), with acknowledgment that the manuscript was first published in Journal of Applied Holistic Nursing Science
5. The author guarantees that the original article, written by the authors named, has not been previously published, does not contain statements that are illegal, does not infringe upon the rights of others, and is subject to copyright exclusively held by the authors.
6. If the article is co-authored by more than one author, each submitting author guarantees that they have been authorized by all co-authors to agree to the copyright and licensing notice (agreement) on their behalf and agrees to inform co-authors of the terms of this policy.Journal of Applied Holistic Nursing Science will not be held liable for any issues arising from internal disputes between authors.
License:
Journal of Applied Holistic Nursing Science is published under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). This license allows anyone to:
Copy and redistribute the material in any medium or format, and remix, transform, and build upon the material, even for commercial purposes, as long as they credit the author for the original creation.
